Advocacy News

NHIA comments on california senate bill 958

April 26, 2022

This week, NHIA submitted comments on California SB 958, the Medication and Patient Safety Act of 2022

NHIA supports amendments to the proposed legislation that allow for infused medications to be administered in the enrollee’s home when the physician and patient determine it is in the patient’s best interest. 

NHIA objects to any efforts to restrict access to home infusion and rejects language that implies office-based infusions are safer than administering medications at home and cited studies published by the National Home Infusion Foundation.  The association also shared context for the unique expertise of home infusion providers and special considerations, standards and protocols that they develop to serve their patients. 

NHIA voiced support for additional amendments that require physicians to inform patients of all payer-supported site-of-care options for receiving infused and injected medications, similar to a requirement recently included in legislation passed by Congress as part of the 21st Century Cures. 

NHIA’s comments also supported restrictions on patient’s transporting their own infusion medications (I.e. brown bagging). 

Finally, NHIA’s comments expressed concern that the conditions for coverage or payment described in the proposed legislation are unnecessary and could increase the overall cost of medications for patients.

Related Posts

Considerations for Addressing ExactaMix Automated Compounding Device (ACD) Valve Set Supply Disruption

On April 19, 2022, Baxter announced a supply disruption of the ExactaMix valve sets (ExactaMix 1200 Valve Set H938792 and ExactaMix 2400 Valve Set H938724) due to raw material constraints that are impacting production volumes. As a result, healthcare providers and institutions are driven to consider conservation measures when compounding using the ExactaMix Automated Compounder.

Read More »

NHIA Submits Comments on DIR Proposed Rule

NHIA submitted comments on a CMS proposed rule: Medicare and Medicaid Programs; CY 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs, which would alter the way pharmacy price concessions, including direct and indirect remuneration (DIR fees), are calculated by pharmacy benefit managers (PBMs).

Read More »